Free Trial
OTCMKTS:BIXT

Bioxytran (BIXT) Stock Price, News & Analysis

Bioxytran logo
$0.16 +0.00 (+1.21%)
As of 03:58 PM Eastern

About Bioxytran Stock (OTCMKTS:BIXT)

Key Stats

Today's Range
$0.16
$0.16
50-Day Range
$0.10
$0.18
52-Week Range
$0.06
$0.23
Volume
81,458 shs
Average Volume
243,761 shs
Market Capitalization
$15.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Bioxytran Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
19th Percentile Overall Score

BIXT MarketRank™: 

Bioxytran scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Bioxytran.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bioxytran is -15.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bioxytran is -15.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.01% of the outstanding shares of Bioxytran have been sold short.
  • Short Interest Ratio / Days to Cover

    Bioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bioxytran has recently decreased by 66.40%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bioxytran does not currently pay a dividend.

  • Dividend Growth

    Bioxytran does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the outstanding shares of Bioxytran have been sold short.
  • Short Interest Ratio / Days to Cover

    Bioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bioxytran has recently decreased by 66.40%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bioxytran has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.
  • Search Interest

    1 people have searched for BIXT on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bioxytran insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    70.00% of the stock of Bioxytran is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Bioxytran's insider trading history.
Receive BIXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter.

BIXT Stock News Headlines

“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
See More Headlines

BIXT Stock Analysis - Frequently Asked Questions

Bioxytran's stock was trading at $0.0899 at the start of the year. Since then, BIXT shares have increased by 76.9% and is now trading at $0.1590.
View the best growth stocks for 2025 here
.

Bioxytran, Inc. (OTCMKTS:BIXT) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.02) EPS for the quarter.

Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), bluebird bio (BLUE), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX).

Company Calendar

Last Earnings
5/15/2025
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:BIXT
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$4.47 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
-7.86

Miscellaneous

Free Float
26,440,000
Market Cap
$15.74 million
Optionable
Not Optionable
Beta
1.82
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (OTCMKTS:BIXT) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners